Aethlon Medical Announces Activation Of Royal Adelaide Hospital To Begin Patient Screening And Enrollment In Hemopurifier Cancer Trial
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical has activated the Royal Adelaide Hospital to begin patient screening and enrollment for its Hemopurifier cancer trial. This trial focuses on patients with solid tumors not responding to anti-PD-1 antibodies.

September 16, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical has initiated patient screening for its Hemopurifier cancer trial at Royal Adelaide Hospital. This trial targets patients with solid tumors not responding to anti-PD-1 antibodies, marking a significant step in their clinical research.
The activation of the Royal Adelaide Hospital for the Hemopurifier trial is a critical development for Aethlon Medical. It signifies progress in their clinical research efforts, potentially leading to advancements in cancer treatment. This could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100